Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer
暂无分享,去创建一个
Xiaoping Zhou | Tao Zhang | Jun-Li Liu | Xiaoyu Han | You Qin | Yu-Ting Li | Jing Tian | J. Tian | Zhang Tao | Jun-li Liu
[1] Yan Wang,et al. Decreased albumin-to-alkaline phosphatase ratio predicted poor survival of resectable gastric cancer patients. , 2021, Journal of gastrointestinal oncology.
[2] Hailun Xie,et al. Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Cancer: A Meta-Analysis , 2020, BioMed research international.
[3] Xiaoli Guo,et al. Prognostic effect of pretreatment albumin-to-alkaline phosphatase ratio in human cancers: A meta-analysis , 2020, PloS one.
[4] Yue Yang,et al. Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid Cancers: A meta-Analysis with trial sequential analysis. , 2020, International journal of surgery.
[5] Wei Jiang,et al. Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer , 2020, Cancer medicine.
[6] Meng-Xin Tian,et al. Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma , 2020, Journal of Cancer.
[7] Feifei Li,et al. Albumin-to-Alkaline Phosphatase Ratio Associates with Good Prognosis of Hepatitis B Virus-Positive HCC Patients , 2020, OncoTargets and therapy.
[8] Lianyu Chen,et al. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis , 2020, BMC Cancer.
[9] Wei-min Li,et al. Albumin-to-alkaline phosphatase ratio at diagnosis predicts survival in patients with metastatic non-small-cell lung cancer , 2019, OncoTargets and therapy.
[10] D. Heo,et al. The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis , 2019, Cancer research and treatment : official journal of Korean Cancer Association.
[11] Jinming Yu,et al. Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer. , 2019, Future oncology.
[12] K. Hanazaki,et al. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer , 2018, Gastric Cancer.
[13] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[14] Yongsheng Song,et al. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis , 2018, Cancer management and research.
[15] Yan Zhang,et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer , 2018, Medicine.
[16] Y. Teng,et al. Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer , 2018, Journal of clinical laboratory analysis.
[17] H. Weir,et al. Liver cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.
[18] Li Zhang,et al. Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer , 2017, Medical science monitor : international medical journal of experimental and clinical research.
[19] David K. Espey,et al. Stomach cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.
[20] Weidong Wei,et al. Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer , 2016, Journal of Cancer.
[21] Yun-zhao Chen,et al. Preoperative Body Mass Index, Blood Albumin and Triglycerides Predict Survival for Patients with Gastric Cancer , 2016, PloS one.
[22] Ken Kato,et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer , 2016, Journal of Cancer Research and Clinical Oncology.
[23] V. Wong,et al. Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma , 2015, Disease markers.
[24] J. Barkin,et al. Stomach , 2015, The American Journal of Gastroenterology.
[25] S. Hong,et al. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis , 2014, Journal of Cancer Research and Clinical Oncology.
[26] L. Helyer,et al. Prognostic factors in metastatic gastric cancer: results of a population-based, retrospective cohort study in Ontario , 2014, Gastric Cancer.
[27] F. Başak,et al. CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[28] J. Lee,et al. The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma , 2013, World Journal of Surgical Oncology.
[29] N. Ohkohchi,et al. Evaluation of serum high‐density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients , 2012, Journal of gastroenterology and hepatology.
[30] Yun-Fei Xia,et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma , 2012, Chinese journal of cancer.
[31] F. Lordick,et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) , 2010, British Journal of Cancer.
[32] C. Shanahan,et al. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? , 2008, Kidney international.
[33] Masahiro Takeuchi,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.
[34] F. Otto,et al. Gene deregulation in gastric cancer. , 2005, Gene.
[35] W. Harb,et al. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. , 2005, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
[36] G. Barnett,et al. Presurgical Serum Albumin Levels Predict Survival Time from Glioblastoma Multiforme , 1999, Journal of Neuro-Oncology.
[37] L. Walker,et al. Serum albumin: a prognostic indicator in patients with colorectal cancer. , 1998, Journal of the Royal College of Surgeons of Edinburgh.